EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 152 filers reported holding EAGLE PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is 0.87 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3 | -100.0% | 230 | -83.7% | 0.00% | – |
| Q3 2020 | $59,000 | -66.9% | 1,410 | -62.2% | 0.00% | – |
| Q2 2020 | $178,000 | -82.6% | 3,729 | -83.2% | 0.00% | -100.0% |
| Q1 2020 | $1,023,000 | +8.8% | 22,257 | -4.6% | 0.00% | -33.3% |
| Q4 2018 | $940,000 | +473.2% | 23,341 | +882.8% | 0.00% | +200.0% |
| Q3 2018 | $164,000 | +33.3% | 2,375 | +1.1% | 0.00% | -80.0% |
| Q1 2018 | $123,000 | -60.5% | 2,348 | -59.7% | 0.01% | -61.5% |
| Q4 2017 | $311,000 | +95.6% | 5,830 | +117.5% | 0.01% | +116.7% |
| Q3 2017 | $159,000 | +200.0% | 2,681 | +299.0% | 0.01% | +100.0% |
| Q4 2016 | $53,000 | -44.2% | 672 | -71.4% | 0.00% | -62.5% |
| Q1 2016 | $95,000 | -81.3% | 2,351 | -59.0% | 0.01% | -80.0% |
| Q4 2015 | $508,000 | +39.9% | 5,737 | +27.6% | 0.04% | +33.3% |
| Q2 2015 | $363,000 | – | 4,495 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 112,666 | $1,777 | 0.65% |
| Smith, Graham & Co., Investment Advisors, LP | 273,099 | $4,306,771 | 0.54% |
| BRANDES INVESTMENT PARTNERS, LP | 1,134,363 | $17,888,904 | 0.35% |
| TANG CAPITAL MANAGEMENT LLC | 118,857 | $1,874,375 | 0.26% |
| Virtus Investment Advisers, Inc. | 20,867 | $329,073 | 0.22% |
| DENALI ADVISORS LLC | 32,300 | $509,371 | 0.18% |
| Nebula Research & Development LLC | 11,473 | $180,929 | 0.10% |
| SCOUT INVESTMENTS, INC. | 131,192 | $1,995,430 | 0.05% |
| XTX Topco Ltd | 15,050 | $237,339 | 0.04% |
| PDT Partners, LLC | 19,745 | $311,379 | 0.04% |